PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Petros Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.00+0.00 (+5.56%)
Close on Oct 19, 2026
- Market cap
- $135.07K
- P/E (TTM)
- –
- Dividend yield
- –
Petros Pharmaceuticals, Inc. revenue by segment
By business segment
| Revenue | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $850.29K | $718.30K | $806.45K | $775.71K | $765.82K | $748.90K | $1.01M | $1.01M | $779.77K | $682.90K | $854.34K | $940.40K | 117.2% | +11.0% |
| Prescription Medications | – | $858.06K | $615.02K | $613.10K | – | $925.76K | $984.41K | $1.51M | $18.33K | -$2.14M | $3.33M | $1.52M | – | – |
By product or service
By region
| Revenue | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $364.78K | $178.40K | $316.04K | $209.96K | $362.70K | $177.67K | $396.18K | $359.20K | $259.14K | $189.64K | $324.60K | $419.55K | 50.3% | +0.6% |
| United States | $360.63K | $1.40M | $1.11M | $1.18M | – | $1.50M | $1.60M | $2.16M | $538.96K | -$1.65M | $3.86M | $2.05M | 49.7% | – |
From the segment and revenue-disaggregation notes of Petros Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.